AMFA Glycovectors Platform

The mannose 6‑phosphate receptor (M6PR) is a ubiquitously expressed endocytic receptor that mediates both cellular internalization and trafficking to lysosomes. Harnessing this endogenous pathway enables controlled intracellular routing of engineered therapeutic constructs.

NanoMedSyn has developed proprietary synthetic derivatives of mannose 6‑phosphate, known as AMFA, which bind M6PR — a key entry route naturally used by M6P‑bearing proteins to reach lysosomes.

AMFA‑Therapeutics Chimeras are designed to exploit the native M6PR‑mediated lysosomal transport pathway. This strategy expands the functional reach of antibody‑based and biologic modalities by enabling access to intracellular and lysosome‑associated targets that are otherwise inaccessible.

AMFA‑Therapeutics consist of an AMFA ligand that engages M6PR, conjugated to a therapeutic payload such as an antibody, enzyme, nanoparticle, or biologic.

By binding M6PR at the cell surface, AMFA‑Therapeutics leverage the receptor’s natural endocytic cycle to shuttle their attached therapeutic cargo into endosomes and subsequently to lysosomes.

This engineered trafficking pathway enables efficient cellular uptake, enhanced lysosomal delivery, and targeted degradation or activation of disease‑relevant molecules within intracellular and lysosomal compartments.